RT Journal Article
T1 Chronic glaucoma induced in rats by a single injection of fibronectin-loaded PLGA microspheres: IOP-dependent and IOP-independent eurodegeneration
A1 Munuera, Inés
A1 Aragón Navas, Alba
A1 Villacampa, Pilar
A1 González-Cela Casamayor, Miriam Ana
A1 Subías, Manuel
A1 Pablo, Luis E.
A1 García Feijoo, Julián
A1 Herrero Vanrell, María Del Rocío
A1 García Martín, Elena Salobrar
A1 Bravo Osuna, Irene
A1 Rodrigo, María J.
AB To evaluate a new animal model of chronic glaucoma induced using a single injection of fibronectin-loaded biodegradable PLGA microspheres (Ms) to test prolonged therapies. 30 rats received a single injection of fibronectin-PLGA-Ms suspension (MsF) in the right eye, 10 received non-loaded PLGA-Ms suspension (Control), and 17 were non-injected (Healthy). Follow-up was performed (24 weeks), evaluating intraocular pressure (IOP), optical coherence tomography (OCT), histology and electroretinography. The right eyes underwent a progressive increase in IOP, but only induced cohorts reached hypertensive values. The three cohorts presented a progressive decrease in ganglion cell layer (GCL) thickness, corroborating physiological age-related loss of ganglion cells. Injected cohorts (MsF > Control) presented greater final GCL thickness. Histological exams explain this paradox: the MsF cohort showed lower ganglion cell counts but higher astrogliosis and immune response. A sequential trend of functional damage was recorded using scotopic electroretinography (MsF > Control > Healthy). It seems to be a function–structure correlation: in significant astrogliosis, early functional damage can be detected by electroretinography, and structural damage can be detected by histological exams but not by OCT. Males presented higher IOP and retinal and GCL thicknesses and lower electroretinography. A minimally invasive chronic glaucoma model was induced by a single injection of biodegradable Ms.
YR 2024
FD 2024
LK https://hdl.handle.net/20.500.14352/105779
UL https://hdl.handle.net/20.500.14352/105779
LA eng
NO Int. J. Mol. Sci. 2024, 25(1), 9; https://doi.org/10.3390/ijms25010009
NO Instituto de salud Carlos III de Madrid
NO Ministerio de Economía y Competitividad (España)
NO Ministerio de Ciencia e Innovación (España)
DS Docta Complutense
RD 6 abr 2025